(Q57470962)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

4 references

30 September 2020

26 October 2020

22 December 2020

24 August 2022

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

hepatocellular carcinoma

2 references

30 September 2020

26 October 2020

2 references

30 September 2020

26 October 2020

1 reference

30 September 2020

antineoplastic resistance

1 reference

hypoxia-inducible factor 1

26 October 2020

1 reference

22 December 2020

Carolina Méndez-Blanco

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Flavia Fondevila

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Javier González-Gallego

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

José L. Mauriz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

author name string

Andrés García-Palomo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

language of work or name

English

0 references

publication date

12 October 2018

5 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

30 September 2020

26 October 2020

22 December 2020

24 August 2022

Experimental and Molecular Medicine

5 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

30 September 2020

26 October 2020

22 December 2020

24 August 2022

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

page(s)

1-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

28 April 2020

copyright license

4 references

30 September 2020

26 October 2020

22 December 2020

24 August 2022

0 references

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Advanced Hepatocellular Cancer: the Current State of Future Research

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Modulation of Autophagy by Sorafenib: Effects on Treatment Response

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

New knowledge of the mechanisms of sorafenib resistance in liver cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Cisplatin based adjuvant chemoradiation following neoadjuvant chemotherapy and surgery in advanced oral cavity cancers: A deliverable regimen?

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia-inducible factors as molecular targets for liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia inducible factors in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Advances in Hypoxia-Mediated Mechanisms in Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resist

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0159-1

7 January 2021

A novel oxygen carrier "YQ23" suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells.

1 reference

12 December 2020

The role of hypoxia inducible factor-1 in hepatocellular carcinoma

1 reference

12 December 2020

Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.

1 reference

12 December 2020

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models

1 reference

12 December 2020

Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria

1 reference

12 December 2020

Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

1 reference

12 December 2020

10.1038/S12276-018-0159-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30315182%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

PubMed publication ID

30315182

1 reference